Evaluation of adverse drug reactions in medical intensive care units

[1]  Martha K. Fees,et al.  On-site pharmacists in the ED improve medical errors. , 2012, The American journal of emergency medicine.

[2]  J. Roh,et al.  Causality Assessment of Cutaneous Adverse Drug Reactions , 2011, Annals of dermatology.

[3]  B. Erstad,et al.  Interdisciplinary Patient Care in the Intensive Care Unit: Focus on the Pharmacist , 2011, Pharmacotherapy.

[4]  A. M. Reis,et al.  Adverse drug events in an intensive care unit of a university hospital , 2011, European Journal of Clinical Pharmacology.

[5]  A. Wilmer,et al.  Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU , 2009, Intensive Care Medicine.

[6]  Yoon Kim,et al.  Evaluation of a computer-based adverse-drug-event monitor. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  A. Iglar,et al.  Implementation of pharmacy services in a telemedicine intensive care unit. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  R. Aster,et al.  Vancomycin-induced immune thrombocytopenia. , 2007, The New England journal of medicine.

[9]  J. Devlin,et al.  Adverse Drug Event Reporting in Intensive Care Units: A Survey of Current Practices , 2006, The Annals of pharmacotherapy.

[10]  Brian L. Erstad,et al.  Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection , 2006, Critical care medicine.

[11]  S. Hahn,et al.  Signal Detection and Causality Evaluation for Pharmacovigilance , 2005 .

[12]  J. Dingell,et al.  Adverse drug reactions in the ICU: lessons learned. , 2005, Chest.

[13]  T. Brennan,et al.  Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I* , 2004, Quality and Safety in Health Care.

[14]  R. Resar,et al.  Adverse drug event trigger tool: a practical methodology for measuring medication related harm , 2003, Quality & safety in health care.

[15]  R. Schlienger,et al.  Potential drug–drug interactions in the medication of medical patients at hospital discharge , 2003, European Journal of Clinical Pharmacology.

[16]  E. G. Hahn,et al.  Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? , 2001, Alimentary pharmacology & therapeutics.

[17]  A. Wall,et al.  Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .

[18]  D. Bates,et al.  Identifying drug safety issues: from research to practice. , 2000, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[19]  A. Egberts,et al.  Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports , 1999, European Journal of Clinical Pharmacology.

[20]  S. Shapiro,et al.  Calcium channel blockers and the risk of cancer. , 1998, JAMA.

[21]  N. Moore,et al.  Frequency and cost of serious adverse drug reactions in a department of general medicine. , 1998, British journal of clinical pharmacology.

[22]  S D Small,et al.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. , 1998, JAMA.

[23]  D. Bates,et al.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.

[24]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[25]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[26]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[27]  David W. Bates,et al.  Incidence and preventability of adverse drug events in hospitalized adults , 1993, Journal of General Internal Medicine.

[28]  P J Schneider,et al.  Severity-indexed, incident report-based medication error-reporting program. , 1991, American journal of hospital pharmacy.

[29]  T. Brennan,et al.  Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. , 1991 .

[30]  T. Brennan,et al.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.

[31]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.

[32]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[33]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[34]  H. Okamoto.  Vancomycin-induced immune thrombocytopenia. , 2007, The New England journal of medicine.

[35]  김은영,et al.  Implementation and Evaluation of the Computerized Surveillance System to Identify Adverse Drug Events: pilot study , 2005 .

[36]  Neeraj Gilhotra,et al.  Safety monitoring of medicinal products , 2005 .

[37]  홍경섭.  Development of a Korean Algorithm for Causality Assessment of Adverse Drug Reactions , 2002 .

[38]  P. Maurette,et al.  [To err is human: building a safer health system]. , 2002, Annales francaises d'anesthesie et de reanimation.

[39]  G. Schumock,et al.  Focusing on the preventability of adverse drug reactions. , 1992, Hospital pharmacy.